AcuCort AB
AcuCort AB is a Swedish pharmaceutical company that develops and commercializes Zeqmelit®, a fast-dissolving oral film of dexamethasone for acute allergic reactions, croup, chemotherapy-induced nausea, and COVID-19 patients, distributed via licensing partners across Europe and pursuing FDA approval for the US.
- Company typePublic
- Founded-
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What AcuCort AB does
AcuCort AB is a Swedish specialty pharmaceutical company headquartered in Medicon Village, Lund, Sweden, listed on Spotlight Stock Market under the ticker ACUC. The company develops and commercializes Zeqmelit®, a fast-dissolving orodispersible oral film based on the long-established corticosteroid dexamethasone. The product is approved in three strengths (4mg, 6mg, 8mg) and is indicated for severe acute allergic reactions, croup in children, chemotherapy-induced nausea and vomiting, and COVID-19 patients requiring supplemental oxygen. AcuCort received Swedish market authorization in October 2020 and added Denmark, Norway, and Finland in January 2023; it is pursuing FDA market approval for the United States and has filed an iPSP with the FDA.
The company operates a single-asset franchise with ~8 employees and a lean organizational structure. Commercialization is executed exclusively through licensing and distribution partnerships: Unimedic Pharma (a wholly-owned subsidiary of listed MedCap AB) holds Nordic rights (Sweden, Norway, Denmark, Finland), and Glenmark Pharmaceuticals was signed in January 2026 to cover Germany, Netherlands, Czech Republic, Austria, Slovakia, and Ukraine. The proprietary oral-film technology is protected by a granted patent in Brazil (expiring November 4, 2035) and Zeqmelit® trademarks across the EU, UK, Australia, Switzerland, India, Canada, and the USA. Revenue was reported as zero through at least Q1 2023, the first commercial order from Unimedic Pharma arrived in January 2024, and the Swedish pharmacy launch occurred in September 2024, with Norway, Finland, and Denmark following in 2024–2025. The company has been funded through repeated rights issues (2017, 2018, 2019, 2021, 2023, 2025), with the 2023 raise of approximately 30 MSEK earmarked predominantly for FDA process and European commercialization.
AcuCort AB firmographics
Firmographics- Name
- AcuCort AB
- Legal name
- AcuCort AB (publ)
- Website
- https://acucort.se
- Company type
- Public
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AcuCort AB is a Swedish pharmaceutical company that develops and commercializes Zeqmelit®, a fast-dissolving oral film of dexamethasone for acute allergic reactions, croup, chemotherapy-induced nausea, and COVID-19 patients, distributed via licensing partners across Europe and pursuing FDA approval for the US.
- Ownership category
- akta.pro rank
AcuCort AB industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)
Keywords
Where AcuCort AB is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
AcuCort AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Product Sales - Zeqmelit: Revenue from sales of Zeqmelit oral film through distribution partners in approved markets (Sweden, Denmark, Norway, Finland)
- Licensing and Distribution Agreements: Revenue from licensing agreements with distribution partners such as Unimedic Pharma (Nordics) and Glenmark Pharmaceuticals (Central Europe)
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
AcuCort AB product offering
Product offeringCore offering
AcuCort develops and commercializes Zeqmelit®, a fast-dissolving oral film placed on the tongue containing the corticosteroid dexamethasone, available in 4mg, 6mg, and 8mg strengths. It is indicated primarily for severe acute allergic reactions, croup in children, chemotherapy-induced nausea and vomiting, and COVID-19 patients requiring supplemental oxygen. The company sells the product through distribution partners in approved markets and is pursuing FDA registration for the US market.
Product overview
AcuCort AB is a pharmaceutical company with a single core product: Zeqmelit®, a fast-dissolving oral film (mouth film) based on dexamethasone. The company operates a focused product portfolio with Zeqmelit® as the sole marketed pharmaceutical product, approved for multiple indications including severe acute allergic reactions, croup in children, chemotherapy-induced nausea/vomiting, and COVID-19. The company commercializes Zeqmelit® through distribution partners across Nordic markets (Sweden, Norway, Denmark, Finland) and is pursuing global expansion including FDA registration for the US market.
Differentiator
Problem solved
Functional benefit
Products and services
- Zeqmelit® Zeqmelit® is a fast-dissolving oral film placed on the tongue containing the corticosteroid dexamethasone, available in 4mg, 6mg, and 8mg strengths. It is indicated for treatment of severe acute allergic reactions, croup in children, nausea and vomiting from chemotherapy, and for COVID-19 patients needing supplemental oxygen treatment. It is a prescription medication dispensed through pharmacies in approved markets (Sweden, Denmark, Norway, Finland) via distribution partners.
Quantifiable outcome
- 72% of patients prefer oral film over tablet treatment for severe allergic reactions
- +1 more outcomes
Companies that use AcuCort AB
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
AcuCort AB technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
AcuCort AB partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Glenmark PharmaceuticalscoreGlenmark Pharmaceuticals partnership announced January 2026 for marketing and distribution of Zeqmelit in Germany, Netherlands, Czech Republic, Austria, Slovakia, and Ukraine. This extends AcuCort's European market presence beyond the Nordic region.
- Unimedic PharmacoreUnimedic Pharma AB, a Swedish specialty pharmaceutical company and wholly-owned subsidiary of MedCap AB (publ), handles sales and marketing of Zeqmelit in Sweden, Norway, Denmark, and Finland. The partnership marks AcuCort's entry into the commercialization phase. Unimedic Pharma has extensive experience in pharmaceutical sales and marketing across the Nordic region.
- HWF Advokater ABminorLegal advisor to AcuCort in connection with the 2023 rights issue.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
AcuCort AB competitors and assessment
Company assessmentDirect peers
- Orexo AB: Swedish specialty pharmaceutical company developing improved formulations of established substances (e.g., Zubsolv, Abstral). Highly relevant Swedish small-cap pharma peer with similar 'reformulation of known APIs' thesis and partnership-led commercial model.
- Aquestive Therapeutics: A US specialty pharma focused on oral film and orally administered drug delivery technologies (e.g., Sympazan, Libervant). Most direct peer given shared oral-film delivery platform, similar small-cap commercial-stage profile, and prescription pharmaceutical focus.
- Opiant Pharmaceuticals: US specialty pharma developing opioid overdose and addiction treatments with a single-asset focus and partnership-driven commercialization. Comparable small public pharma with single-product concentration and licensing strategy similar to AcuCort.
- IntelGenx Technologies Corp. Canadian specialty pharma developing oral film and oral drug delivery platforms for Rx products. Comparable given proprietary thin-film technology, partnership-driven commercialization model, and small-cap public profile similar to AcuCort.
- TFF Pharmaceuticals: US clinical-stage pharma developing thin-film formulation technology for inhaled and intranasal drug delivery. Comparable given novel drug-delivery platform, partnership-based commercialization, and small-cap public profile.
- NovaBay Pharmaceuticals: US small-cap specialty pharma commercializing prescription products in adjacent specialty/dermatology categories. Comparable scale, public listing profile, and partnership-led commercialization of niche Rx products.
Broad incumbents
- ALK-Abelló A/S: Danish-listed allergy immunotherapy leader with global presence. Relevant incumbent working in the same allergy treatment space that AcuCort's Zeqmelit® targets, though operating in immunotherapy rather than acute symptom management.
Emerging players
- Veriton Pharma: UK specialty pharma focused on reformulation of established medicines including allergy and respiratory products. Comparable niche commercial-stage pharma with reformulation strategy similar to AcuCort's dexamethasone oral film approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AcuCort AB social profiles
Digital presenceAcuCort AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
AcuCort AB leadership team
Management profileNumber of profiles
Profiles9 records
AcuCort AB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AcuCort AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AcuCort AB
What does AcuCort AB do?
AcuCort develops and commercializes Zeqmelit®, a fast-dissolving oral film placed on the tongue containing the corticosteroid dexamethasone, available in 4mg, 6mg, and 8mg strengths. It is indicated primarily for severe acute allergic reactions, croup in children, chemotherapy-induced nausea and vomiting, and COVID-19 patients requiring supplemental oxygen. The company sells the product through distribution partners in approved markets and is pursuing FDA registration for the US market.
Is AcuCort AB a public or private company?
AcuCort AB is a public company. It is classified as public and is currently operating.
When was AcuCort AB founded?
AcuCort AB was founded in -1. It employs 1 to 10 people.
Where is AcuCort AB based?
AcuCort AB is headquartered in Lund, Sweden, in the Europe region.
How does AcuCort AB make money?
Two revenue lines are on record. Product Sales - Zeqmelit is the primary driver. The others are licensing and Distribution Agreements.
Who are AcuCort AB's main competitors?
Direct peers on record are Orexo AB, Aquestive Therapeutics, Opiant Pharmaceuticals, IntelGenx Technologies Corp., TFF Pharmaceuticals and NovaBay Pharmaceuticals. ALK-Abelló A/S is listed as a broad incumbent. Veriton Pharma is listed as an emerging player.
Does AcuCort AB have an API?
No public API is recorded for AcuCort AB.
What industry is AcuCort AB in?
AcuCort AB's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 325411 and its SIC code is 2833.